GlassScriptPhysician profile
Nikhila Kethireddy
NPI 1093249732
$2,011.65
in general payments reported to CMS, 2019-2025
21 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $129 · 2021: $222 · 2022: $407 · 2023: $214 · 2024: $726 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.55 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $430.93 | 2022-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $272.84 | 2020-2025 | Enhertu |
| Tempus Ai, INC | $180.78 | 2024 | Xt Cdx |
| Genentech, INC. | $149.51 | 2025 | Itovebi |
| Regeneron Healthcare Solutions, INC. | $124.76 | 2021 | |
| Celgene Corporation | $114.78 | 2022-2023 | Reblozyl |
| Biontech Se | $110.36 | 2025 | |
| Pfizer INC. | $107.13 | 2020-2024 | |
| Incyte Corporation | $81.22 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.64 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $47.69 | 2024 | |
| Merck Sharp & Dohme LLC | $46.37 | 2024 | Lynparza, Keytruda |
| Eisai INC. | $40.59 | 2020-2024 | |
| Seagen INC. | $38.13 | 2023 | Tukysa |
| Karyopharm Therapeutics INC. | $33.92 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.42 | 2021 | |
| Kite Pharma, INC. | $32.29 | 2022 | |
| Blueprint Medicines Corporation | $28.54 | 2022 | |
| Daiichi Sankyo INC. | $27.36 | 2024 | Enhertu |
| Genentech USA, INC. | $20.28 | 2022 | |
| Genzyme Corporation | $19.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhila Kethireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.